Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Clinical trial NCT07493408 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07493408
Sponsor: The University of Hong Kong
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)Blastic Transformation of Chronic Myeloid Leukemia Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)Haematopoietic Stem Cell Transplant, Allogeneic

Start date: 2026-03-30
Primary completion: 2035-12-31
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.